Work

Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs23-po4-19-06

Authors: Neelima Vidula, Senthil Damodaran, Manali Bhave, Hope Rugo, Ami N. Shah, Erica Blouch, Nathan Royce Ruffle-Deignan, Ogadinma Ogbenna, Lisa E. Flaum, Massimo Cristofanilli, Joseph Sparano, Harry Ostrer, Vandana Abramson, Nora Horick, Aditya Bardia

Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Emory University, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Northwestern University, Weill Cornell Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Albert Einstein College of Medicine, Vanderbilt University Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4396587286

Cites:

Cited by: 1

Related to: 10